Epigenetix
Biotechnology, 1004 BRKS Ln, Delray Beach, Florida, 33483, United States, 11-50 Employees
Phone Number: +19*********
Who is EPIGENETIX
Epigenetix is a clinical stage pharma company with a first-in-class oral cancer drug about to begin phase on trials at 5 leading US cancer centers. We will include patients with prostate ...
Read More
- Headquarters: 1004 BRKS Ln, Delray Beach, Florida, 33483, United States
- Date Founded: 2011
- Employees: 11-50
- Revenue: Under $1 Million
- Active Tech Stack: See technologies
- CEO: Joseph Collard
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from EPIGENETIX
Epigenetix Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Epigenetix
Answer: Epigenetix's headquarters are located at 1004 BRKS Ln, Delray Beach, Florida, 33483, United States
Answer: Epigenetix's phone number is +19*********
Answer: Epigenetix's official website is https://epigenetix.com
Answer: Epigenetix's revenue is Under $1 Million
Answer: Epigenetix's SIC: 2834
Answer: Epigenetix has 11-50 employees
Answer: Epigenetix is in Biotechnology
Answer: Epigenetix contact info: Phone number: +19********* Website: https://epigenetix.com
Answer: Epigenetix is a clinical stage pharma company with a first-in-class oral cancer drug about to begin phase on trials at 5 leading US cancer centers. We will include patients with prostate cancer, pancreatic cancer, breast cancer, sarcoma, NUT carcinoma and other cancers where our drug has shown unprecedented anti-cancer activity. Our drug was selected among many other drug candidates to potently inhibit three different validated cancer drug targets: p300/CBP + BRD4+ CECR2. Treatment results in elimination of both the tumor itself as well as associated metastases. This powerful drug fights cancer in multiple ways: (1) by eradicating tumor cells directly (cytotoxic therapy), (2) by unleashing the bodys immune system (immunotherapy), and (3) by inhibiting cancer-inducing male and female hormone actions (hormone therapy). While presently pursued as monotherapy, synergy with checkpoint inhibitors, PARP inhibitors, CDK4/6 inhibitors as well as epigenetic drugs, such as EZH2 inhibitors ,has been shown preclinically.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month